India changes patent law to meet WTO treaty, making new medicines less available to most citizens, other countries.
India changed its pharmaceutical patent law to conform to the U.S.-European system, just ahead of a Jan. 1 World Trade Organization deadline--meaning that most new medicines (patentable in 1995 or later) will be priced out of reach of the great majority of people in India--and in Africa and other poor regions as well. "The real issue for the multinational corporations is not the poor-country markets, which are financially small and unattractive, but the poor-country examples. How would thousands of people in rich countries, especially the U.S., be persuaded to accept death from cancer and other diseases because they cannot pay tens of thousands of dollars a year for a new generation of treatments that could save their lives--if companies in India could manufacture and sell the same treatments for a small fraction of the price?"
James
John S
JS
D003132:Commerce / Q000458:organization & administration*; D007194:India; D007391:International Cooperation; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D004364:Pharmaceutical Preparations / Q000600:supply & distribution*
D004364:Pharmaceutical Preparations